• Juliana Costa Albuquerque, Rosane Aline Magalhães, Jamille Araújo Félix, Maria Vilani Rodrigues Bastos, Juvenia Bezerra Fontenele, Nádia Mendonça Trompieri, and Francisco Helder Cavalcante Felix.
• Universidade Federal do Ceará, FortalezaCeará, Brazil, Pharmacy Student, Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brazil.
• Sao Paulo Med J. 2014 Jan 1; 132 (1): 485448-54.

Context And ObjectiveHemangiomas are the commonest vascular tumors during childhood. In 2008, the effect of propranolol for treating capillary hemangiomas was demonstrated. Other similar results followed, showing that it rapidly reduces lesion volume. The objective here was to evaluate children and adolescents with hemangiomas that were treated with propranolol.Design And SettingRetrospective study, conducted in a children's hospital.MethodsPatients aged 0-19 years with or without previous treatment, who were treated between January 2009 and December 2010, were included. The response was assessed by comparing the lesion appearance between the start of treatment and the last consultation. We considered partial or complete responses as the response to treatment.ResultsSixty-nine patients with a median follow-up of 11 months (mean age: 31 months) were included. Of these, 58 patients were recently diagnosed and 11 had had previous treatment. A response (partial or complete) was seen in 60 patients (87%). Among the capillary hemangioma cases, responses were seen in 50 out of 53 (94%), while in other lesion types, it was 10 out of 16 (63%) (P = 0.3; chi-square). Responses in patients less than one year of age were seen in 37 out of 38 (97%), whereas in those over one year of age, in 23 out of 31 (74%) (P = 0.4; chi-square). Side effects were uncommon and mild.ConclusionsPropranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients.

25 keywords...

hide…